Gene-environment interaction in major depression and antidepressant treatment response

Current Psychiatry Reports

Volumn 14, Issue 2, 2012, Pages 129-137

  Keers, Robert ^a   Uher, Rudolf ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressant medication; Antidepressant response; Childhood maltreatment; Depression; Gene environment interactions; Major depression; Pharmacogenetics; Stressful life events

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESCITALOPRAM; FK 506 BINDING PROTEIN; FLUOXETINE; INTERLEUKIN 11; NEUTROPHIC TYROSINE KINASE RECEPTOR TYPE 2; NORTRIPTYLINE; RETINOID RELATED ORPHAN RECEPTOR ALPHA; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SULFOTRANSFERASE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; URONYL 2 SULFOTRANSFERASE;

ALLELE; BDNF GENE; CREB1 GENE; CRHR1 GENE; ENVIRONMENTAL FACTOR; FKBP5 GENE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEREDITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IL11 GENE; MAJOR DEPRESSION; NRC31 GENE; PATHOGENESIS; REVIEW; RISK FACTOR; RORA GENE; SLC6A4 GENE; STRESS; TREATMENT RESPONSE; UST GENE; GENETICS; LIFE EVENT; MENTAL STRESS; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GENE-ENVIRONMENT INTERACTION; HUMANS; LIFE CHANGE EVENTS; RISK FACTORS; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84860625810     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-011-0251-x     Document Type: Review

References (96)

1. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard School of Public Health; 1996.
2. *D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. (Pubitemid 43050100)
3. Steimer W, Muller B, Leucht S, Kissling W. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta. 2001;308(1-2):33-41. (Pubitemid 32537608)
4. Klengel T, Binder EB. Using gene-environment interactions to target personalized treatment in mood disorder. Pers Med. 2011;8(1):12.
5. Uher R. The implications of gene-environment interactions in depression: will cause inform cure? Mol Psychiatry. 2008;13(12):1070-8.
6. Keers R, Aitchison KJ. Pharmacogenetics of antidepressant response. Expert Rev Neurother. 2011;11(1):101-25.
7. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552-62.
8. Mazure CM. Life stressors as risk factors in depression. Clin Psychol Sci Pract. 1998;5(3):291-313. (Pubitemid 128543430)
9. Kendler KS, Gardner CO. Monozygotic twins discordant for major depression: a preliminary exploration of the role of environmental experiences in the aetiology and course of illness. Psychol Med. 2001;31(3):411-23. (Pubitemid 32294039)
10. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry. 2010;167(11):1305-20.
11. McGuffin P, Katz R, Watkins S, Rutherford J. A hospital-based twin register of the heritability of DSM-IV unipolar depression. Arch Gen Psychiatry. 1996;53(2):129-36. (Pubitemid 26049389)
12. Lewis CM, Ng MY, Butler AW, Cohen-Woods S, Uher R, Pirlo K, et al. Genome-wide association study of major recurrent depression in the U. K. population. Am J Psychiatry. 2010;167(8):949-57.
13. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, et al. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry. 2010;15(6):589-601.
14. Shi J, Potash JB, Knowles JA, Weissman MM, Coryell W, Scheftner WA, et al. Genome-wide association study of recurrent early-onset major depressive disorder. Mol Psychiatry. 2011;16(2):193-201.
15. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry. 2011;16(2):202-15.
16. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry. 2009;14(4):359-75.
17. Wray NR, Pergadia ML, Blackwood DH, Penninx BW, Gordon SD, Nyholt DR et al. Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned. Mol Psychiatry. 2010. doi:10.1038/mp. 2010.109.
18. Widom CS, DuMont K, Czaja SJ. A prospective investigation of major depressive disorder and comorbidity in abused and neglected children grown up. Arch Gen Psychiatry. 2007;64(1):49-56. (Pubitemid 46041738)
19. Wise LA, Zierler S, Krieger N, Harlow BL. Adult onset of major depressive disorder in relation to early life violent victimisation: a case-control study. Lancet. 2001;358(9285):881-7. (Pubitemid 32900571)
20. Scott KM, Smith DR, Ellis PM. Prospectively ascertained child maltreatment and its association with DSM-IV mental disorders in young adults. Arch Gen Psychiatry. 2010;67(7):712-9.
21. Clark C, Caldwell T, Power C, Stansfeld SA. Does the influence of childhood adversity on psychopathology persist across the lifecourse? A 45-year prospective epidemiologic study. Ann Epidemiol. 2010;20(5):385-94.
22. Gilbert R, Widom CS, Browne K, Fergusson D, Webb E, Janson S. Burden and consequences of child maltreatment in high-income countries. Lancet. 2009;373(9657):68-81.
23. Brown GW, Bifulco A, Harris TO. Life events, vulnerability and onset of depression: some refinements. Br J Psychiatry. 1987;150:30-42. (Pubitemid 17081815)
24. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-9. (Pubitemid 36877077)
25. Munafo MR, Durrant C, Lewis G, Flint J. Gene × environment interactions at the serotonin transporter locus. Biol Psychiatry. 2009;65(3):211-9.
26. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA. 2009;301(23):2462-71.
27. Uher R, McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression:2009 update. Mol Psychiatry. 2010;15(1):18-22.
28. Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry. 2011;68(5):444-54. This is the most recent metaanalysis of the most extensively studied G×E in MDD. This paper reports a significant interaction between the 5-HTTLPR and environmental adversity on the development of depression. It also suggests that interaction effects may be stronger for measures of childhood maltreatment than recent stressors and in studies using objective or interview-based measures of stressors rather than self-report questionnaires.
29. Uher R, Caspi A, Houts R, Sugden K, Williams B, Poulton R, et al. Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results. J Affect Disord. 2011;135(1-3):56-65.
30. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res. 2007;41(12):979-90. (Pubitemid 47301944)
31. Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Kim YH, et al. Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders. Biol Psychiatry. 2007;62(5):423-8. (Pubitemid 47284032)
32. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112(2):257-69. (Pubitemid 36144114)
33. Aguilera M, Arias B, Wichers M, Barrantes-Vidal N, Moya J, Villa H, et al. Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol Med. 2009;39(9):1425-32.
34. Hosang GM, Uher R, Keers R, Cohen-Woods S, Craig I, Korszun A, et al. Stressful life events and the brain-derived neurotrophic factor gene in bipolar disorder. J Affect Disord. 2010;125(1-3):345-9.
35. Juhasz G, Dunham JS, McKie S, Thomas E, Downey D, Chase D, et al. The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactions. Biol Psychiatry. 2011;69(8):762-71.
36. Horstmann S, Binder EB. Glucocorticoids as predictors of treatment response in depression. Harv Rev Psychiatry. 2011;19(3):125-43.
37. Tyrka AR, Price LH, Gelernter J, Schepker C, Anderson GM, Carpenter LL. Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry. 2009;66(7):681-5.
38. Cicchetti D, Rogosch FA, Oshri A. Interactive effects of corticotropin releasing hormone receptor 1, serotonin transporter linked polymorphic region, and child maltreatment on diurnal cortisol regulation and internalizing symptomatology. Dev Psychopathol. 2011;23(4):1125-38.
39. Schmid B, Blomeyer D, Treutlein J, Zimmermann US, Buchmann AF, Schmidt MH, et al. Interacting effects of CRHR1 gene and stressful life events on drinking initiation and progression among 19-year-olds. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale. Neuropsychopharmacologicum (CINP). 2011;13(6):703-14.
40. DeYoung CG, Cicchetti D, Rogosch FA. Moderation of the association between childhood maltreatment and neuroticism by the corticotropinreleasing hormone receptor 1 gene. J Child Psychol Psychiatry. 2011;52(8):898-906. doi:10.11 11/j.1469-7610.2011.02404.x.
41. Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry. 2008;65(2):190-200. (Pubitemid 351214318)
42. Polanczyk G, Caspi A, Williams B, Price TS, Danese A, Sugden K, et al. Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. Arch Gen Psychiatry. 2009;66(9):978-85.
43. Kranzler HR, Feinn R, Nelson EC, Covault J, Anton RF, Farrer L, et al. A CRHR1 haplotype moderates the effect of adverse childhood experiences on lifetime risk of major depressive episode in African-American women. Am J Med Genet B Neuropsychiatr Genet. 2011;156(8):960-8.
44. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319-25. (Pubitemid 39577942)
45. Ising M, Depping AM, Siebertz A, Lucae S, Unschuld PG, Kloiber S, et al. Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci. 2008;28(2):389-98.
46. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, et al. Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA. 2008;299(11):1291-305. (Pubitemid 351439075)
47. Xie P, Kranzler HR, Poling J, Stein MB, Anton RF, Farrer LA, et al. Interaction of FKBP5 with childhood adversity on risk for posttraumatic stress disorder. Neuropsychopharmacology. 2011;35(8):1684-92.
48. Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, et al. Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology. 2011;36(10):1982-91. doi:10.1038/npp. 2011.81.
49. Zimmermann P, Bruckl T, Nocon A, Pfister H, Binder EB, Uhr M, et al. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry. 2011;168(10):1107-16.
50. Bet PM, Penninx BW, Bochdanovits Z, Uitterlinden AG, Beekman AT, van Schoor NM, et al. Glucocorticoid receptor gene polymorphisms and childhood adversity are associated with depression: new evidence for a gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(5):660-9.
51. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473-500. doi:10.1038/mp. 2008.116.
52. Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, et al. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics. 2008;9(7):841-6.
53. Perlis RH, Fijal B, Adams DH, Sutton VK, Trivedi MH, Houston JP. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry. 2009;65(9):785-91.
54. *D) cohort. Biol Psychiatry. 2008;63(12):1103-10.
55. Chi MH, Chang HH, Lee SY, Lee IH, Gean PW, Yang YK, et al. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord. 2010;126(3):430-5. doi:10.1016/j. jad.2010.07.006.
56. Zou YF, Wang Y, Liu P, Feng XL, Wang BY, Zang TH, et al. Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Hum Psychopharmacol. 2011;25(2):145-52.
57. Licinio J, O'Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry. 2004;9(12):1075-82. (Pubitemid 40065452)
58. Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett. 2007;414(2):155-8. (Pubitemid 46273990)
59. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009;9(4):225-33.
60. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010;68(6):536-43. doi:10.1016/j.biopsych.2010.04.034. This is the most recent meta-analysis of the 5-HTTLPR and response to antidepressant treatment. The study reports no effects of genotype on response to treatment. There was considerable heterogeneity of effects between studies that was not explained by previously suggested moderators, including age, ethnicity, geographic location, or study duration.
61. Zou YF, Wang F, Feng XL, Li WF, Tao JH, Pan FM, et al. Metaanalysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci Lett. 2011;484(1):56-61.
62. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res. 2006;1118(1):176-82.
63. Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord. 2007;104(1-3):83-90. (Pubitemid 350052308)
64. Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry. 2009;14(12):1105-18.
65. Brouwer JP, Appelhof BC, van Rossum EF, Koper JW, Fliers E, Huyser J, et al. Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 2006;31(10):1154-63. (Pubitemid 44803086)
66. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66(9):966-75.
67. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67(2):133-8.
68. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167(5):555-64.
69. Ishii M, Maeda N. Oversulfated chondroitin sulfate plays critical roles in the neuronal migration in the cerebral cortex. J Biol Chem. 2008;283(47):32610-20.
70. Jetten AM, Kurebayashi S, Ueda E. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol. 2001;69:205-47. (Pubitemid 33804679)
71. DUAG Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990;18:7.
72. Horacek J, Rozehnalova E, Rosslerova H, Dvorak A. The influence of stressful life events on development of depression and treatment response in the population of patients in higher age. Cesk Slov Psychiat. 2011;106(5):311-7.
73. Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry. 2011;19(3):109-24.
74. Keers R, Uher R, Gupta B, Rietschel M, Schulze TG, Hauser J, et al. Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. J Affect Disord. 2010;127(1-3):337-42.
75. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry. 2011. doi:10.1176/appi. ajp. 2011.11020335. This is the first meta-analysis of the effects of childhood maltreatment on course of illness and treatment response in depression. Childhood maltreatment was associated with both an elevated risk of developing recurrent and persistent depressive episodes and a lack of response or remission during treatment of depression.
76. Miniati M, Rucci P, Benvenuti A, Frank E, Buttenfield J, Giorgi G, et al. Clinical characteristics and treatment outcome of depression in patients with and without a history of emotional and physical abuse. J Psychiatr Res. 2010;44(5):302-9.
77. Kaplan MJ, Klinetob NA. Childhood emotional trauma and chronic posttraumatic stress disorder in adult outpatients with treatmentresistant depression. J Nerv Ment Dis. 2000;188(9):596-601.
78. Enns MW, Cox BJ. Psychosocial and clinical predictors of symptom persistence vs remission in major depressive disorder. Can J Psychiatry. 2005;50(12):769-77. (Pubitemid 43161771)
79. Sakado K, Sato T, Uehara T, Sakado M, Someya T. Perceived parenting pattern and response to antidepressants in patients with major depression. J Affect Disord. 1999;52(1-3):59-66. (Pubitemid 29232034)
80. Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, et al. Treatment of selective serotonin reuptake inhibitorresistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry. 2009;48(3):330-9.
81. Johnstone JM, Luty SE, Carter JD, Mulder RT, Frampton CM, Joyce PR. Childhood neglect and abuse as predictors of antidepressant response in adult depression. Depress Anxiety. 2009;26(8):711-7.
82. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 2008;8(2):90-100. (Pubitemid 351411545)
83. Tomaszewska W, Peselow ED, Barouche F, Fieve RR. Antecedent life events, social supports and response to antidepressants in depressed patients. Acta Psychiatr Scand. 1996;94(5):352-7. (Pubitemid 26396312)
84. Mandelli L, Marino E, Pirovano A, Calati R, Zanardi R, Colombo C, et al. Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur Neuropsychopharmacol. 2009;19(1):64-7.
85. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, et al. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J. 2011;11(2):138-45. This is the largest study to date to explore G×E as predictors of antidepressant treatment response. It reports a significant interaction between the 5-HTTLPR and SLEs on response to the SSRI escitalopram, but not for the TCA nortriptyline.
86. Bukh JD, Bock C, Vinberg M, Werge T, Gether U, Kessing LV. No interactions between genetic polymorphisms and stressful life events on outcome of antidepressant treatment. Eur Neuropsychopharmacol. 2010;20(5):327-35.
87. Zielinski DS. Child maltreatment and adult socioeconomic well-being. Child Abuse Negl. 2009;33(10):666-78.
88. Brown GW, Craig TK, Harris TO, Handley RV. Parental maltreatment and adulthood cohabiting partnerships: a life-course study of adult chronic depression-4. J Affect Disord. 2008;110(1-2):115-25.
89. Brown GW, Harris TO. Depression and the serotonin transporter 5-HTTLPR polymorphism: a review and a hypothesis concerning gene-environment interaction. J Affect Disord. 2008;111(1):1-12.
90. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A. 2003;100(24):14293-6. (Pubitemid 37499230)
91. Bulmash E, Harkness KL, Stewart JG, Bagby RM. Personality, stressful life events, and treatment response in major depression. J Consult Clin Psychol. 2009;77(6):1067-77.
92. Lewis CC, Simons AD, Nguyen LJ, Murakami JL, Reid MW, Silva SG, et al. Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2010;49(2):132-40.
93. Simons AD, Gordon JS, Monroe SM, Thase ME. Toward an integration of psychologic, social, and biologic factors in depression: effects on outcome and course of cognitive therapy. J Consult Clin Psychol. 1995;63(3):369-77.
94. Eley TC, Hudson JL, Creswall C, Tropeano M, Lester KJ, Cooper P, et al. Therapygenetics: The 5HTTLPR and response to psychological therapy. Mol Psychiatry. doi:101038/mp2011132.2011. This is the first study to examine genetic predictors of response to cognitive-behavioral therapy. It reports that (in contrast to findings from antidepressant response studies) individuals with the SS genotype of the 5-HTTLPR respond more favorably to treatment.
95. Smeraldi E, Zanardi R, Benedetti F, Di BD, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3(6):508-11. (Pubitemid 28515526)
96. Van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S, et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry. 2006;59(8):681-8.